12 Best Small Cap Pharma Stocks to Buy Now

Page 5 of 10

6. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Number of Hedge Fund Holders: 27

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a specialty company focused on developing and selling medications for central nervous system (CNS) diseases, including epilepsy, migraine, ADHD, and Parkinson’s disease. The company has built a strong presence in the CNS market with well-known products like Qelbree for ADHD, Trokendi XR, and Oxtellar XR for epilepsy, and treatments for Parkinson’s disease such as Apokyn and Gocovri.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reported strong financial results for Q3 2024, with total revenues reaching $175.7 million, a 14% increase from the previous year. Net product sales grew to $170.3 million, which was driven by the success of key products like Qelbree and Gocovri. Operating earnings surged to $40.9 million, while net earnings improved significantly to $38.5 million, or $0.69 per diluted share, compared to a loss in the same period last year.

Qelbree, a non-stimulant ADHD treatment, saw a 68% increase in sales, reaching $62.4 million in Q3 2024. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is also expanding its pipeline with promising drug candidates like SPN-830, SPN-817, and SPN-820, positioning the company for continued growth in the CNS market.

Page 5 of 10